EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q4 EPS of ($0.81), $0.06 worse than the analyst estimate of ($0.75). Revenue for the quarter came in at $620 thousand versus the consensus estimate of $1.05 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.